ClinicalTrials.gg
CompletedNCT07252908Updated Jun 18, 2026

A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

A Phase 2 interventional study of TQC3721 inhalation powder and Placebo for TQC3721 inhalation powder in Pulmonary Disease, Chronic Obstructive, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 29 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Enrollment
6th of 17
195 · median 113
Started
2025
with 4 others
Phase 2
8 of 17
none open now
Registered
14th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 6th largest by enrollment, is one of 5 that started in 2025, is one of 8 in phase 2, and was the 14th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the form before the trial and have a full understanding of the trial content, process, and potential adverse reactions.
  • Be willing and able to adhere to the trial visit schedule and procedures and use the dry powder inhaler correctly.
  • Male and female subjects aged 40 to 80 years (inclusive).
  • (BMI) within the range of 18-30 kg/m² (inclusive).
  • Subjects have no plans for pregnancy and voluntarily adopt effective measures from screening to at least 1 month after the last use of the study drug.
  • 12-lead (ECG) showing: heart rate of 50-100 beats per minute (bpm); interval (QTcF) \<= 450 msec for males or \<= 470 msec for females.
  • Diagnosed with according to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and have had symptoms consistent with COPD for at least 1 year before screening.
  • Have been on stable background inhaled therapy for COPD for at least 4 weeks before screening.
  • Be able to perform acceptable and reproducible pulmonary function tests.
  • At the screening visit (V1 visit), after administration of a bronchodilator (4 puffs of salbutamol), the /Forced Vital Capacity (FVC) ratio \< 0.7, and 30% predicted value \<= FEV1 \< 80% predicted value.
  • Clinically stable COPD within 4 weeks before the screening visit (V1 visit) and between the V1 visit and V2 visit.
  • Modified Medical Research Council (mMRC) Dyspnea Scale score >= 2 at screening.
  • Meet the concurrent medication restrictions (within the time intervals specified in the protocol) and are expected to maintain the restriction requirements during treatment.
  • Smoking history >= 10 pack-years (pack-year: number of packs per day × number of smoking years; e.g., 1 pack (20 cigarettes) per day for 10 consecutive years, or 10 cigarettes per day for 20 consecutive years).

Exclusion criteria

Exclusion Criteria:

  • Life-threatening history, including admission to the intensive care unit (ICU) and/or requirement for intubation.
  • COPD exacerbation requiring systemic therapy within 3 months before the screening visit (V1 visit) or before the randomization visit (V2 visit).
  • Hospitalization history due to COPD or pneumonia ≥ 1 time within 6 months before screening.
  • Antibiotic treatment for upper and/or lower respiratory tract infections within 6 weeks before screening or before the randomization visit (V3 visit). Note: Subjects with a history of lower respiratory tract infection within 6 weeks cannot be enrolled, but may be rescreened 6 weeks after recovery from the infection.
  • Concurrent other respiratory diseases: α-1 antitrypsin deficiency, primary ciliary dyskinesia, lung cancer; active pulmonary infections, pulmonary tuberculosis, bronchiectasis, pulmonary fibrosis, sarcoidosis, pulmonary hypertension, asthma, and other respiratory diseases as assessed by the investigator.
  • Clinically significant abnormalities found on chest computed tomography (CT) that are not caused by COPD and judged by the investigator to have an impact on trial results or patient safety. If there is no chest CT report within 6 months before Visit 1, a chest CT examination must be performed at Visit 1.
  • Previous pulmonary resection or lung volume reduction surgery.
  • Pulmonary rehabilitation therapy (those whose treatment has been stable for 4 weeks before screening and will remain stable during the trial may be enrolled).
  • Receipt of oral corticosteroids or roflumilast for COPD within 3 months before the screening visit (V1 visit), or receipt of oral theophylline and/or theophylline derivatives for COPD within 1 week before the screening visit (V1 visit).
  • Use of non-selective oral beta-blockers.
  • Previous treatment with TQC3721.
  • Patients who received immunotherapy (e.g., azathioprine, cyclophosphamide) within 4 weeks before the screening period.
  • As assessed by the investigator, the patient cannot discontinue the prohibited drugs specified in the protocol during the screening and treatment phases of this study.
  • The patient has a history of currently uncontrolled diseases, including but not limited to endocrine, thyroid, neuropsychiatric, hepatic, gastrointestinal, renal, hematologic, urinary, immunologic, or ophthalmic diseases, which are judged to be clinically significant by the investigator.
  • History or current evidence of clinically significant cardiovascular diseases, defined as any disease that the investigator believes would endanger the patient's safety if participating in the study, or any disease that may affect the efficacy or safety analysis if the disease/condition deteriorates during the study; subjects with any of the following conditions at Visit 1 will be excluded:

    1. Myocardial infarction, unstable angina, or stroke within the past 6 months;
    2. Unstable or life-threatening arrhythmias requiring intervention within the past 3 months;
    3. (NYHA) Class III-IV heart failure.
  • Unstable or uncontrolled hypertension (systolic blood pressure >= 160 mmHg and diastolic blood pressure >= 100 mmHg after drug control).
  • Patients with poorly controlled type 2 diabetes or fasting blood glucose > 10 mmol/L.
  • Receipt of major surgery (requiring general anesthesia) within 8 weeks before the screening visit (V1 visit), failure to fully recover from the surgery at the time of screening (V1 visit), or planned surgery before the end of the study.
  • History of malignant tumors (cured or uncured) of any organ or system within the past 5 years (excluding non- cutaneous basal cell or squamous cell carcinoma, or cervical carcinoma in situ that have been cured for more than 5 years before the screening period).
  • Clinically significant abnormal values in safety laboratory tests (hematology, biochemistry, or urinalysis) determined by the investigator at the screening visit (V1 visit), including but not limited to one of the following:

    1. (ALT) or Aspartate Aminotransferase (AST) > 2 × (ULN); alkaline phosphatase > 2 × ULN; total > 1.5 × ULN;
    2. Estimated (eGFR) calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \< 60 mL/min/1.73m².
  • Positive test result for (HIV) antibody; positive test result for Surface Antigen (HBsAg) (if HBsAg is positive, Hepatitis B Virus (HBV) DNA testing may be added if necessary; subjects with HBV DNA \< Lower Limit of Quantification (LLOQ) need not be excluded); positive Virus (HCV) antibody with confirmed presence of HCV ribonucleic acid (RNA); positive Treponema Pallidum Particle Agglutination (TPPA) antibody.
  • Intolerance or allergy to salbutamol or other inhaled bronchodilator therapies for COPD.
  • Patients requiring continuous or intermittent oxygen therapy.
  • Female subjects who are pregnant, lactating, or planning to become pregnant during the study enrollment period.
  • Receipt of within 28 days before randomization, receipt of inactivated vaccine within 7 days before randomization, or planned vaccination during the study.
  • History of drug abuse or alcoholism within the past 3 years (consumption of 14 units of alcohol per week: 1 unit = 360 ml of beer, or 45 ml of spirits with 40% alcohol content, or 150 ml of wine).
  • Participation in any drug or medical device clinical trial within 4 weeks or 5 drug half-lives (whichever is longer) before screening.
  • Other conditions deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    750 µg Dosage group

    750 µg TQC3721 inhalation powder,administered by inhalation,twice a day for 4 weeks.

    Drug: TQC3721 inhalation powder

  • Experimental
    1000 µg Dosage group

    1000µg TQC3721 inhalation powder,administered by inhalation,twice a day for 4 weeks.

    Drug: TQC3721 inhalation powder

  • Placebo comparator
    Placebo for TQC3721 inhalation powder

    Placebo for TQC3721 inhalation powder, administered by inhalation, twice a day for 4 weeks.

    Drug: Placebo for TQC3721 inhalation powder

Interventions

  • TQC3721 inhalation powder is target inhibitor.

  • DrugPlacebo for TQC3721 inhalation powder

    Placebo for TQC3721 inhalation powder.

06

What researchers measure

Primary outcomes

  1. Change of the maximum value of Forced Expiratory Volume in the first second (FEV1)

    Change of the maximum value of FEV1 was determined from baseline to four weeks after treatment.

    Time frame: From baseline to four weeks after treatment

Secondary outcomes

  1. Number of subjects of changes in the peak, trough values of FEV1 and average FEV1 AUC

    Number of subjects of changes in the peak, trough values of FEV1 and average FEV1 Area under the curve (AUC) within 3 hours and 12 hours after morning administration on 1 day, 2 weeks and 4 weeks of treatment compared with the baseline.

    Time frame: From baseline to four weeks after treatment

  2. Valley concentration

    Evaluating valley concentration of TQC3721 (in selected patients only).

    Time frame: From baseline to four weeks after treatment

  3. Adverse Events (AE)

    The subjets with the number, frequency, incidence, and severity of adverse events, serious adverse events, and adverse events associated with investigational drugs (including investigational drugs and control drugs), as well as abnormal laboratory indicators were evaluated.

    Time frame: From baseline to safety visit(about 5 weeks after first dosing)

  4. Frequency of rescue medication used during the study

    Frequency of rescue medication used during the study compared to placebo group

    Time frame: From baseline to four weeks after administration

  5. Changes in Chronic obstructive pulmonary disease Assessment Test (CAT)

    Changes in CAT assessment after 2 and 4 weeks of treatment compared with baseline.The CAT questionnaire is mainly used to assess the impact of COPD on patients' health and daily quality of life.There are 8 questions in the CAT, and each question is scored 0-5 points, with the higher score meaning the more severe symptoms.

    Time frame: From baseline to four weeks after treatment

  6. Changes in St. George's Respiratory Questionnaire (SGRQ)

    Changes in SGRQ after 2 and 4 weeks of treatment compared with baseline. The SGRQ is a standardized self-assessment tool used to evaluate the quality of life of patients with chronic respiratory diseases. It quantifies the degree of impairment in patients' symptoms, activity capacity and social psychological adaptation, and comprehensively reflects the impact of the disease on patients' daily lives.

    Time frame: From baseline to four weeks after treatment

  7. Peak concentration

    Evaluating peak concentration of TQC3721 (in selected patients only)

    Time frame: From baseline to four weeks after treatment

  8. Area under the concentration-time curve from 0 to last observation (AUC 0-t) of TQC3721

    Evaluating Area under the concentration-time curve from 0 to last observation (AUC 0-t) of TQC3721. (in selected patients only)

    Time frame: From baseline to four weeks after treatment

  9. Apparent volume of distribution (Vd/F)

    Evaluating Vd/F of TQC3721. (in selected patients only)

    Time frame: From baseline to four weeks after treatment

  10. Apparent clearance (CL/F)

    Evaluating Apparent clearance (CL/F) of TQC3721. (in selected patients only)

    Time frame: From baseline to four weeks after treatment

  11. Half-ife (t1/2)

    Evaluating the time required for half of the drug to be eliminated from the plasma of TQC3721. (in selected patients only)

    Time frame: From baseline to four weeks after treatment

07

Study locations

29 sites
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chognqing 400010, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • Jiangmen Central Hospital
    Jiangmen, Guangdong 529000, China
  • Guigang People's Hospital
    Guigang, Guangxi 537100, China
  • Zunyi Medical University Affiliated Hospital
    Zunyi, Guizhou 563000, China
  • Puyang Oilfield General Hospital
    Puyang, Henan 457001, China
  • Yichang Central People's Hospital
    Yichang, Hubei 443003, China
  • The People's Hospital of Liuyang
    Changsha, Hunan 410000, China
  • Xiangtan County People's Hospital
    Xiangtan, Hunan 411200, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 010000, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210000, China
  • Yixing People'S Hospital
    Wuxi, Jiangsu 214000, China
  • Jiujiang First People's Hospital
    Jiujiang, Jiangxi 332000, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • Siping Central People's Hospital
    Siping, Jilin 136099, China
  • Heze Municipal Hospital
    Heze, Shandong 274000, China
  • Shanghai JiaoTong University of medicine Ruijin Hospital
    Shanghai, Shanghai Municipality 20025, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
  • Linfen People's Hospital
    Linfen, Shanxi 41000, China
  • Nuclear Industry 416 Hospital
    Chengdou, Sichuan 610051, China
  • Chengdu Fifth People's Hospital
    Chengdu, Sichuan 610044, China
  • Affiliated Hospital Of ChengDu University
    Chengdu, Sichuan 610081, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan Sichuan 610044, China
  • Suining Central Hospital
    Suining, Sichuan 629000, China
  • Yibin Second People's Hospital
    Yibin, Sichuan 644000, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • The Fourth Central Hospital of Tianjin
    Tianjin, Tianjin Municipality 300140, China
  • Taizhou central hospital (Taizhou university hospital)
    Taizhou, Zhejiang 31800, China
  • The 2th School of Medicine ,WMU/The 2th affiliated Hospital and Yuying Children's Hospital of WMU
    Wenzhu, Zhejiang 325027, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Apr 2026, 4 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Dec 22, 2025
Primary completionActual
Apr 28, 2026
CompletionActual
May 7, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07252908
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Dec 22, 2025
Primary completion
Apr 28, 2026
Completion
May 7, 2026
Last update
Jun 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC3721

Start the discussion